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Background:  There are no published data regarding fracture risk in type 2 diabetic patients in Korea. In this study, we compared 
the fracture incidence and risk of osteoporosis of type 2 diabetic female patients with those in a non-diabetic hypertensive cohort.
Methods:  The incidence of fracture in a type 2 diabetic cohort was compared with that in a non-diabetic hypertensive cohort 
over the course of 7 years. Female type 2 diabetic and non-diabetic hypertensive patients who visited Eulji General Hospital out-
patient clinic from January 2004 to April 2004 were assigned to the diabetic cohort and the non-diabetic hypertensive cohort, re-
spectively. Surveys on fracture event, use of anti-osteoporosis medications, and bone mineral density were performed. 
Results:  The number of fractures was 88 in the female diabetic cohort (n=1,268, 60.6±11.5 years) and 57 in the female non-dia-
betic hypertensive cohort (n=1,014, 61.4±11.7 years). The RR in the diabetic cohort was 1.38 (P=0.064; 95% confidence interval 
[CI], 0.98 to 1.94) when adjusted for age. Diabetic patients with microvascular complications (61.0%) showed a higher RR of 1.81 
(P=0.014; 95% CI, 1.13 to 2.92) compared with those without these complications. The prevalence of osteoporosis was compara-
ble between the groups, while use of anti-osteoporosis medication was more common in the diabetic cohort (12.8%) than in the 
hypertensive cohort (4.5%) (P<0.001).
Conclusion:  In our study, a higher fracture risk was observed in female type 2 diabetics with microvascular complications. Spe-
cial concern for this risk group is warranted.
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INTRODUCTION
Osteoporosis occurring in diabetic patients causes a signifi-
cant financial and physical burden. Furthermore hip or verte-
bral fractures are frequently accompanied by severe disabilities 
which can be potentially fatal [1]. Until recently, the associa-
tion between type 2 diabetes and osteoporosis has been con-
troversial. In general, type 2 diabetes patients tend to have a 
higher body mass index (BMI) compared to non-diabetics. 
Even when bone mineral density (BMD) is high, osteoporotic 
fractures are known to be more common in diabetic patients 
[2-4]. However, there have been a few studies on the risk of os-
teoporotic fractures in type 2 diabetes patients, according to 
which, the risk of vertebral fractures and distal radius fractures, 
unlike hip fractures, does not increase in such individuals [4]. 
  Very few studies exist on hip and overall fractures in Asian 
diabetics. Opinions vary regarding the reasons behind the in-
creased risk of fracture in type 2 diabetes patients. It is suggest-
ed that increase in falling tendency as a result of peripheral 
neuropathy, retinopathy, postural hypotension, and hypogly-
cemia might play a role. At the molecular level, the use of oral 
hypoglycemic agents such as Thiazolidinedione (TZD); the 
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accumulation of advanced glycation end product (AGE); and 
changes in AGE receptors (RAGE) are known to play an im-
portant role in bone metabolism and bone strength. It was also 
suggested that bone turnover rate is decreased in diabetic pa-
tients [5-8]. 
  In order to investigate the association between type 2 diabe-
tes and bone fractures, researchers collected data regarding the 
prevalence of osteoporosis and osteoporotic fractures in female 
type 2 diabetes patients. 
METHODS 
Study method and subjects
This study was a retrospective cohort study performed on fe-
male patients over 20 years old who had been treated for dia-
betes. The study was performed at Eulji General Hospital, en-
rolling patients who visited outpatient clinic from January 1, 
2004 to April 30, 2004. The control group included hyperten-
sive females over 20 years old who had visited Cardiology De-
partment outpatients clinic during the same period. This study 
compared the two groups for likelihood of incurring fractures. 
The study concluded on December 31, 2010, for a total study 
duration of 7 years.
  Each subject was surveyed for gender, height, weight, HbA1c 
and creatinine levels, duration of diabetes, bone density, event 
of fracture, and whether the subject had diabetes, hyperten-
sion, or developed diabetic microvascular complications. 
  Regarding the use of drugs, the use of anti-osteoporosis 
drugs, insulin, sulfonylurea, thiazolidinedione, metformin, 
beta-blockers, thiazide, statin, and tranquilizers was surveyed. 
Bone density was measured from the lumbar and femoral ar-
eas using dual-energy X-ray absorptiometry (DEXA) (GE Lu-
nar DEXA; GE Lunar, Madison, WI, USA). For postmeno-
pausal females or females over 50 years who were unsure if 
they were menopausal, a T-score was used, whereas a Z-score 
was used for premenopausal females and females under 50 
years with unclear menopausal status. Females with T-scores 
greater than -1.0 were defined as normal, and females with T-
scores between -1.0 and -2.5 were defined as having osteope-
nia. Osteoporosis was defined by a T-score less than -2.5. Z-
scores less than -2.0 were defined as ‘below the expected range 
for age.’ Patients who took oral hypoglycemic agents or received 
insulin treatment were placed in the diabetic patient group, and 
non-diabetic patients taking anti-hypertensive drugs were 
placed in the hypertensive group. 
  Patients were exempted from this study if they had pre-ex-
isting fractures, a malignant tumor, or were on dialysis for 
chronic renal failure. Patients with an estimated GFR (eGFR) 
less than 30 mL/min/1.73 m
2 were exempted as well. eGFR 
was calculated using the following formula: Estimated GFR 
(mL/min/1.73 m
2)=186×(creat/88.4)
-1.154×(age)
-0.203×(0.742, 
if female)×(1.210, if black) [9]. 
  HbA1c was measured through high performance liquid 
chromatography using HLC-723G7 (Tosoh, Tokyo, Japan). 
Analysis was confined to the patients who visited outpatient 
clinic or admitted to the hospital at least once a year. 
  Fractures in the vertebra, hip, distal radius, proximal hu-
merus, pelvis, and ankle (tibia and fibula) were examined, 
while fractures of the cranium, cervical vertebra, fingers and 
toes were excluded from the analysis [10]. Multiple fractures 
from primary trauma such as car accidents were also excluded 
from the analysis. 
  The fractures analyzed in this study included those newly 
diagnosed at Eulji General Hospital as well as other hospitals 
by using medical records review. 
  Every year, the number of patients exposed to risk was com-
puted, and through that computation, the fracture rate per 
thousand patients per year was arithmetically estimated. More-
over, the relative risk (RR) of fractures in the diabetic group 
compared to that in the non-diabetic hypertensive group was 
computed, and the fracture-free survival of both groups was 
compared. 
Statistical analysis
The mean values and the standard deviations were calculated 
for each variable by using SPSS statistics software version 17.0 
(SPSS Inc., Chicago, IL, USA). To analyze the differences be-
tween the groups, Student’s t-tests or chi-square tests were 
conducted accordingly. The calculation of RR was performed 
using Cox’s proportional hazards model, and fracture-free 
survival was calculated via life table method. The differences 
between the two groups were compared using Gehan’s gener-
alized Wilcoxon statistic. The significance level was set at P<
0.05. 
RESULTS
Clinical characteristics of subjects
There were a total of 2,282 participants. The diabetes group 
consisted of 1,268 patients, and the hypertension group con-146
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sisted of 1,014 patients. The clinical characteristics of the sub-
jects are shown in Table 1. The mean age of the diabetes group 
was 60.6±11.5 years, and that of the hypertension group was 
61.4±11.7 years. There was no significant difference in the 
mean ages of the two groups, and BMI and creatinine levels 
also showed no significant differences (Table 1). The use of be-
ta-blockers, thiazide, and statin, which are known to affect 
fractures, was high in the hypertensive group, and there was 
no difference in the use of tranquilizers between the two groups 
(Table 1). The mean observation period was 5.7±2.0 years in 
the diabetes group and 5.3±2.2 in the hypertensive group, 
which was significantly longer in the diabetes group (P<0.001). 
During the observation period, 60 patients in the hypertensive 
group developed diabetes. There was no difference in the prev-
alence of osteoporosis/osteopenia between both groups when 
compared according to bone density (Table 2). However, when 
the BMD of the spine and hip were compared in the postmeno-
pausal patients, the femoral neck BMD of the hypertension 
group was lower than that in the diabetes group (Table 3). The 
usage rate of anti-osteoporosis medication was significantly 
higher in the diabetic group (n=162, 12.8%) than the hyper-
tension group (n=46, 4.5%) (P<0.001). Prior to study conduc-
tion, there was no difference in the usage rate of anti-osteopo-
rosis medication in the two groups, with 15 (1.2%) patients 
from the diabetes group and 5 (0.5%) patients from the con-
trol group (P=0.070). When all drugs were compared, the use 
of biphosphates, estrogen, and raloxifene did not differ (P=
0.134) (Table 4).
Incidence of fracture 
During the study period, 88 members of the diabetes group 
Table 1.  Clinical characteristics of the study population
Characteristic DM Control P value
Age, yr 60.6±11.5 61.4±11.7 0.071
BMI, kg/m
2 25.1±3.4 24.8±3.4 0.154
DM duration, yr 9.6±7.5
HbA1c, % 7.67±1.50 5.75±0.46 <0.001
Creatinine, mg/dL 0.83±0.18 0.83±0.15 0.582
eGFR, mL/min/1.73 m
2 67.0±16.9 67.5±14.7 0.039
Normal/Microalbumin-
uria/Overt proteinuria
498/462/126 
(39.3/36.4/9.9)
Peripheral neuropathy 246 (19.4)
Retinopathy 150 (11.8)
Insulin/TZD/SU/MET 449/171/571/521 
(35.4/13.5/45.0/41.1)
Beta-blocker 68 (5.4) 195 (19.2) <0.001
Thiazide 23 (1.8) 76 (7.5) <0.001
Statin 185 (14.6) 175 (17.6) 0.009
Tranquilizer 82 (6.5) 76 (7.5) 0.336
Values are presented as either mean±standard deviation or number 
(%). Significance at P<0.05 according to Student’s t-test or chi-square 
test. 
DM, diabetes mellitus; BMI, body mass index; eGFR, estimated glo-
merular filtration rate; TZD, thiazolidinedione; SU, sulfonylurea; MET, 
metformin.
Table 2.  Comparison of the prevalence of osteoporosis be-
tween the diabetic and non-diabetic hypertensive groups
Lumbar Hip
DM Control DM Control
Premenopause (Z-score)
Normal 45 (93.8) 12 (85.7) 52 (96.3) 16 (94.1)
≤-2.0 3 (6.3) 2 (14.3) 2 (3.7) 1 (5.9)
P value 0.331 0.697
Postmenopause (T-score)
Normal 135 (30.8) 47 (29.4) 107 (25.1) 24 (17.5)
Osteopenia 200 (45.7) 69 (43.1) 227 (53.2) 77 (56.2)
Osteoporosis 103 (23.5) 44 (27.5) 93 (21.8) 36 (26.3)
P value 0.605   0.162 
Values are presented as number (%). Significance at P<0.05 accord-
ing to chi-square test. 
DM, diabetes mellitus.
Table 3.  Comparison of bone mineral density between the di-
abetic and non-diabetic hypertensive groups
DM Control
P value
No. Mean±SD No. Mean±SD
Premenopause (Z-score)
L2-4 48 0.02±1.26 14 -0.15±1.29 0.167
Femur neck 46 -0.36±1.12 13 -0.54±0.74 0.589
Trochanter 46 -0.12±1.04 13 -0.08±0.59 0.881
Total hip 46 -0.04±1.07 13 -0.08±0.76 0.881
Postmenopause (T-score)
L2-4 438 -1.63±1.64 160 -1.72±1.30 0.557
Femur neck 427 -1.50±1.09 137 -1.71±0.98 0.045
Trochanter 427 -1.35±1.10 137 -1.40±1.10 0.669
Total hip 427 -1.32±1.16 137 -1.40±1.10 0.446
Values are presented as mean±standard deviation. Significance at P<
0.05 according to Student’s t-test.
DM, diabetes mellitus; SD, standard deviation.147
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and 56 members of the hypertension group incurred bone 
fractures. When converted to an annual incidence rate, 16.9 
individuals per thousand diabetics had incurred fractures, 
while 15.5 individuals per thousand hypertensive patients had 
incurred fractures. The mean age at which patients were diag-
nosed with fractures was 69.1±9.8 years, while that for pa-
tients with hypertension was 74.9±9.6 years, a significant dif-
ference (P=0.001). Overall, among patients who were diag-
nosed with fractures, 66 (44.9%) had vertebral fractures, 32 
(21.8%) had hip fractures, 27 (18.4%) had distal radius frac-
tures, and 22 (15.0%) were diagnosed with fractures in other 
areas. In the diabetes group, the diagnosis rates were 39.8%, 
22.7%, 17.0%, and 20.5% for vertebral fractures, hip fractures, 
distal radial fractures, and other fractures, respectively, and in 
the hypertensive patient group, these diagnosis rates were 
52.5%, 20.3%, 20.3%, and 6.8%, respectively, a non-significant 
difference (P=0.112) (Table 5). Among the “other fractures” in 
the diabetes group, 5 (5.7%) were pelvic fractures, 8 (9.1%) were 
ankle fractures, 5 (5.7%) were fractures of the humerus. These 
fractures numbered 2 (3.5%), 1 (1.8%), and 1 (1.8%), respec-
tively, in the hypertensive group. 
Comparing incidence of fractures in the diabetic group and 
the hypertensive group
When the mean annual fracture rate of the diabetic group was 
compared to the hypertensive group, the fracture rate of the 
diabetic group was 1.09 times higher. The comparison of RR 
of fracture was performed using the Cox regression model. 
The results showed an unadjusted RR of 1.21 (P=0.259; 95% 
confidence interval [CI], 0.87 to 1.70) and an RR of 1.38 after 
adjusting for age (P=0.064; 95% CI, 0.98 to 1.94). When frac-
ture-free survival was compared using the life table method, 
diabetic group was comparable to the hypertensive group (P=
0.13) (Fig. 1). When 1,936 postmenopausal women were ana-
lyzed, the mean fracture rate per thousand individuals in the 
diabetes group was 18.9 patients, and that in the hypertensive 
group was 18.1 patients. In the Cox regression analysis, the RR 
of postmenopausal diabetic females was 1.22 (P=0.276; 95% 
CI, 0.85 to 1.73), and 1.37 (P=0.085; 95% CI, 0.96 to 1.95) af-
ter adjusting for age. In the subgroup analysis after excluding 
those who took anti-osteoporosis medications for the preven-
tion of fractures, osteoporotic fractures were confirmed to be 
higher in the diabetic group (age adjusted RR, 2.507 [P=0.035; 
95% CI, 1.07 to 5.89]).
  When fractures were classified as vertebral or non-vertebral 
fractures, the risk of non-vertebral fracture increased signifi-
cantly in the diabetes group; RR was 1.62 when adjusted for 
age (P=0.041; 95% CI, 1.02 to 2.56). There was no significant 
difference in hip fractures between these groups, but the RR of 
Table 4.  Comparison of the use of anti-osteoporosis medica-
tions between the diabetic and non-diabetic hypertensive 
groups 
DM Control
Bisphosphonate 122 (75.3) 34 (73.9)
Sex hormone 36 (22.2) 8 (17.4)
Raloxifen 4 (2.5) 4 (2.5)
Total 162 46
P value 0.134
Values are presented as number (%). Significance at P<0.05 according 
to chi-square test. 
DM, diabetes mellitus.
Table 5.  Comparison of fracture sites between the diabetic 
and non-diabetic hypertensive groups 
DM Control Total
Vertebrae 35 (39.8) 31 (52.5) 66 (44.9)
Hip 20 (22.7) 12 (20.3) 32 (21.8)
Distal radius 15 (17.0) 12 (20.3) 27 (18.4)
Elsewhere 18 (20.5) 4 (6.8) 22 (15.0)
Total 88 57 147
P value 0.112
Values are presented as number (%). Significance at P<0.05 according 
to chi-square test. 
DM, diabetes mellitus.
Fig. 1.  Comparison of cumulative incidences of fracture be-
tween the diabetic and non-diabetic hypertensive groups. DM, 
diabetes mellitus.
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miscellaneous bone fractures in the diabetes group was signifi-
cantly higher than in the hypertensive group after adjusting for 
age (RR, 3.48 [P=0.024; 95% CI, 1.18 to 10.30]).
Relationship between diabetic complications, use of drugs 
and the incidence of fractures
When the diabetes group was classified based on the presence 
or absence of microvascular complications, 61.0% appeared to 
have microvascular complications. The RR of the patients with 
microvascular complications compared to patients without 
these complications was 1.81 (P=0.014; 95% CI, 1.13 to 2.92) 
and remained significantly high at RR 1.64 after adjusting for 
age (P=0.043; 95% CI, 1.02 to 2.64). The risk of fracture did 
differ significantly with insulin and thiazolidinedione treat-
ments, but when sulfonylurea or metformin were used, the RR 
of fracture appeared to decrease (sulfonylurea, RR, 0.61 [P=
0.028; 95% CI, 0.39 to 0.95]; metformin, RR, 0.43 [P=0.001; 
95% CI, 0.27 to 0.70]), and this effect was statistically signifi-
cant even after adjusting for age. Additionally, there was no 
significant difference in the risk for fracture in the diabetes 
group or in any group when beta-blockers, thiazide, statin, or 
tranquilizers were used. 
DISCUSSION
This study was a retrospective cohort study covering a period 
of 7 years during which the incidence of bone fractures was 
compared between a diabetic group and a non-diabetic hyper-
tensive group. In the results of this study, the incidence of over-
all fractures in the diabetes group was not significantly differ-
ent from that in the non-diabetic hypertensive group. Howev-
er, diabetes was associated with an increase in non-vertebral 
fractures. Although there was no difference in overall bone 
fractures in our study, incidences of fractures occurred at 
younger ages in the diabetes group, and more of the diabetes 
group were taking drugs for osteoporosis. These findings sug-
gest increased fracture risk in type 2 diabetes patients and are 
in line with previous studies [2-4]. 
  In contrast, some studies have reported no increase in the 
risk of fractures in diabetes patients [11,12]. In a subgroup 
analysis in a large-scale Rotterdam study, the risk of fracture 
decreased in patients who had been newly diagnosed with dia-
betes; however, in advanced diabetes patients who were un-
dergoing treatment, the risk increased [12]. Interestingly, a de-
crease in the risk of non-vertebral fractures was observed in 
patients with impaired glucose tolerance [12]. In a recently 
published study, the risk of fracture in recently diagnosed dia-
betes patients initially decreased but then increased after 5 or 
more years [13]. One possible explanation for these results is 
that the increase in insulin level resulting from impaired glu-
cose tolerance and early stages of diabetes may have an influ-
ence on bone metabolism, and the simultaneous increase in 
comorbidities as diabetes progresses may play a role [14]. The 
diabetes patients who participated in this study who were re-
ceiving treatment had a mean duration of diabetes of 9.6 years, 
and microvascular complications in diabetic patients appeared 
to be a major risk factor for fractures. 
  In this study, femoral neck BMD was higher in postmeno-
pausal type 2 diabetes patients than in the control group. Ac-
cording to a recent meta-analysis, BMD in type 2 diabetes pa-
tients tends to be higher, femur BMD tends to be lower than 
spinal BMD, and risk of hip fracture also increases [4,15]. In 
this study, femoral BMD was not lower than spinal BMD in 
diabetes patients, and hip fractures did not appear to increase. 
There was no significant difference in the distribution of the 
location of the fractures between the diabetes group and the 
control group, and the most common fracture sites were ver-
tebrae, hip, and distal radius, in descending order. There was 
no significant increase in the risk of vertebral or hip fractures 
in the diabetes group, while the incidences of non-vertebral 
fractures and miscellaneous fractures appeared to be signifi-
cantly different. Although there are no clear causes for the dif-
ferences from results reported in Western studies, ethnic and 
regional differences are assumed to play a role.
  Recently, when the results were analyzed using quantitative 
computed tomography and separating cortical and trabecular 
bone, an increase in the trabecular bone of the spine and femur 
in type 2 diabetes patients was observed, and there was no dif-
ference in the cortical bone. A decrease in bone volume and 
cross-sectional area was observed, but there was no difference 
in terms of load-strength ratio, which partially explains the 
discrepancy between BMD and fracture risk in diabetes [15].
  In a previously published comparative study performed on 
185 female type 2 diabetes patients, the BMD of the lumbar of 
the type 2 diabetes patient group was higher compared to that 
of the age-adjusted healthy control group [16]. The results for 
BMD from this study were limited because data were not col-
lected from every patient. However, BMD of the diabetic group 
did not have a tendency to decrease compared to that in the 
hypertensive group. A significantly higher number of diabetes 149
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patients used osteoporosis drugs compared to hypertensive 
patients, which may be the result of more aggressive osteopo-
rosis screenings in diabetes patients. In our study, patients in 
the diabetic group received BMD examinations 2.3 times more 
frequently than patients in the hypertensive group, and 2.9 
times more patients from the diabetic group took drugs for 
osteoporosis. Even when BMD is similar and the use of osteo-
porosis drugs is higher, the incidences of fracture are assumed 
to be higher because non-skeletal problems that develop in di-
abetes patients contribute to fractures. In other words, loss of 
balance due to peripheral neuropathy, retinopathy, postural 
hypotension, or hypoglycemia is known to increase the risk of 
falling, which could result in fractures. In our study, when pa-
tients had complications such as retinopathy, peripheral neu-
ropathy, and nephropathy, we observed an increase in the risk 
of fracture in diabetes patients. Among oral hypoglycemic 
agents, thiazolidinedione induces bone loss, which can cause 
secondary osteoporosis. Through molecular mechanisms, ad-
vanced glycation end product (AGE) or receptor glycation end 
product (RAGE) play an important role in bone metabolism 
and bone strength [5,7,14]. In addition, macrovascular and 
peripheral vascular complications have been suggested to de-
crease skeletal blood flow, although this is still controversial 
[17]. A decrease of the bone turnover rate has been observed 
in diabetes patients. This increases BMD but concommitantly 
inhibits recovery of bone damage, and it is assumed that this 
will increase the accumulation of microscopic damage [11]. 
More recently, and structural and metabolic changes such as 
low P1NP, and osteocalcin, have been proposed to have influ-
ences [8]. Although the mechanism is not clear, the sulfonyl-
ureas and metformin protect against fractures, as was con-
firmed in this study. However, neither insulin nor thiazolidin-
edion was confirmed to have any effect on fractures [6,18].
  The limitations of this study are as follows. First, although 
there was a control group, it was a non-diabetic hypertensive 
group, and not all hypertensive patients received oral glucose 
tolerance tests or glycated hemoglobin measurements, which 
could have offset the increase in the risk of fracture. Addition-
ally, alternate studies on changes in the risk of fracture due to 
hypertension are necessary. Second, the confirmed results from 
this study are only from one institution. Third, a limitation of 
retrospective study data in general is that data that have been 
missed may have had an influence on the results. In fact, BMD 
data were available only for part of all patients. Fourth, data on 
identification of asymptomatic cases of vertebral fractures is 
limited. 
  Despite these limitations, to our knowledge, this study was 
first to evaluate overall fracture risk over a long term follow up 
period in a large population of type 2 diabetic patients in Ko-
rea. It also provides valuable clinical information such as BMD, 
drug use, and relations to diabetic microvascular complications. 
  In conclusion, an increased tendency in fractures in Korean 
diabetes patients were observed even when they were receiv-
ing more aggressive treatment for osteoporosis and had simi-
lar BMD. Particularly for patients with complications from di-
abetes, more aggressive fracture risk assessment, patient edu-
cation, and appropriate medication are required to reduce the 
risk of fracture, especially as the disease progresses.
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